“…Indeed, the microinfusion of NMDA‐receptor and NOS inhibitors in the IC has been shown to inhibit sound‐evoked electrocortical desynchronization, as measured by EEG in Iannone et al (1996), whereas the microinjection of the NOS inhibitor in the other relay stations of the acoustic pathway, such as the geniculatus medialis, lemniscus lateralis, and olivaris superior nuclei, was seen to have no effect (Nistico, Bagetta, Iannone, & Duca, 1994). In addition, findings from 2019 have shown that both the local delivery of the nNOS inhibitor N G ‐methyl‐L‐arginine (L‐NMMA) and the sGC inhibitor 1H‐[1,2,4]oxadiazolo[4,3‐a]quinolaxine‐1‐one (ODQ) blunts the NMDA‐evoked increase in sound‐driven activity of neurons in the IC using in vivo electrophysiological recordings (Olthof et al, 2019). In humans, hearing loss, which is sometimes associated with anosmia, constitutes a “red flag” for the diagnosis of syndromic forms of congenital hypogonadotropic hypogonadism, such as the Kallmann syndrome (Boehm et al, 2015), and is increasingly recognized as a risk factor for developing dementia (Bowl & Dawson, 2018).…”